FTC Sues WPATH Over Gender Care
Analysis based on 19 articles · First reported Jun 17, 2026 · Last updated Jun 18, 2026
The lawsuit by the United States — Federal Trade Commission against World Professional Association for Transgender Health and other medical organizations creates significant uncertainty and risk for the healthcare industry, particularly for providers of gender-affirming care. This could lead to increased legal costs, potential changes in insurance coverage for such treatments, and a chilling effect on medical organizations' ability to establish and disseminate clinical guidelines, impacting investment in related medical services and technologies.
The United States — Federal Trade Commission, joined by United States — Alaska, United States — Iowa, United States — Nebraska, and United States — Texas, has sued the World Professional Association for Transgender Health (WPATH), alleging deceptive claims about gender-affirming care for minors and that its members profited from these claims. This action is part of President Donald Trump's administration's broader effort to limit gender-affirming care. The lawsuit claims WPATH misrepresented the medical necessity, safety, and efficacy of treatments and failed to disclose side effects, aiming to ensure insurance coverage for procedures. WPATH has called the complaint baseless, asserting that the FTC lacks jurisdiction and is acting out of retaliation, especially after a federal judge temporarily blocked a prior FTC investigation into the organization. The United States — Federal Trade Commission also launched investigations into the American Academy of Pediatrics and the Pediatric Endocrine Society, which also sued the FTC.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard